The AI boom could strengthen Epic's position, health system execs say. Here's where startups and health tech vendors can still win
fiercehealthcare - Clinician-facing AI, imaging AI, patient AI assistants, discharge and care transitions and revenue cycle AI are the categories where health systems are most willing to look beyond Epic, executives said.
AI Summary: Health system executives warn that the surge in AI interest is strengthening incumbent EHR vendors, notably Epic, which can bundle AI features into existing workflows at scale. Startups face an uphill battle unless they target niche integration gaps, interoperability wins or demonstrable ROI — in short, cleverness and agility beat nostalgia for disruption.
- Connecting care: interoperability, prior auth and data exchange (5)
- Epic's AI offensive: UGM rollouts, tools and tokenomics (9)
- Health systems scaling AI: governance, ROI and safety (7)
- Startups and vendors: where to pivot in an Epic world (7)
- All Other Stories
Connecting care: interoperability, prior auth and data exchange
Epic's AI offensive: UGM rollouts, tools and tokenomics
Health systems scaling AI: governance, ROI and safety
Startups and vendors: where to pivot in an Epic world
All Other Stories
AstraZeneca Holds Preliminary Talks with Bristol Myers Squibb on Potential $400 Billion Merger
oncodaily - A deal that could create the world’s fourth-largest drugmaker British pharmaceutical leader AstraZeneca has held confidential, preliminary discussions regarding a potential combination with US rival Bristol Myers Squibb(BMS). A completed […]
AI Summary: AstraZeneca entered preliminary, non-binding talks with Bristol Myers Squibb about a potential $400 billion merger, probing whether combining pipelines and scale could reshape oncology and other businesses. The discussions are early, sparking market speculation and likely regulatory scrutiny as executives weigh strategic synergies against integration complexity and antitrust risk.
How a Deadly Superbug Tricks the Immune System to Survive in Hair Follicles
discovermagazine - Learn how Candida auris takes advantage of the skin’s immune response to stay put inside hair follicles.
AI Summary: Researchers show that Candida auris can persist in hair follicles by rewiring local skin immune responses, creating a hidden reservoir that helps the fungus survive disinfection and spread in healthcare settings. The finding explains persistent colonization and suggests new diagnostic and decolonization strategies focused on follicular niches — because apparently this pathogen likes a good hairdo.
Senate Confirms Dr. Erica Schwartz as C.D.C. Director
Apoorva Mandavilli / nytimes - Dr. Schwartz, a deputy surgeon general in the first Trump administration, has publicly supported childhood vaccines.
AI Summary: Senate confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention after a high-profile nomination process. She will assume leadership of the agency responsible for national disease prevention and public health preparedness, steering CDC policy and operations amid ongoing public‑health challenges and scrutiny of federal responses.
FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
oncodaily - On July 31, 2026, the US Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults […]
AI Summary: The FDA has approved an expanded use for a lutetium‑177 radiopharmaceutical (Pluvicto), broadening access for PSMA‑positive metastatic prostate cancer patients and potentially speeding the adoption of targeted radionuclide therapy. Clinicians note the approval could shift treatment sequencing and patient pathways, with implementation details and eligibility criteria guiding real‑world impact.
- Access, dose optimization and real-world data for Lu-177 (4)
- FDA expands Pluvicto approval; industry reaction (3)
- PSMAddition trial: earlier Lu-177 delays metastatic progression (5)
Access, dose optimization and real-world data for Lu-177
FDA expands Pluvicto approval; industry reaction
PSMAddition trial: earlier Lu-177 delays metastatic progression
Single dose of psilocybin for depression shows promising results in UK's first publicly funded randomized trial
medicalxpress - The first randomized controlled trial in the U.K. has found that a single dose of psilocybin, the active compound found in "magic mushrooms," produced significant improvements in depression compared with a placebo. This is the first publicly funded random…
AI Summary: A publicly funded randomized trial in the UK found that a single dose of psilocybin, delivered in a clinical setting, produced promising improvements for people with treatment-resistant major depressive disorder. The results suggest psychedelic-assisted therapy could be a viable addition to standard care—pending larger trials and careful safety monitoring—challenging old assumptions about one-and-done fixes.
FDA approves first drug for full range of narcolepsy symptoms
medicalxpress - The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults. Orzeyful marks the first medication approved for the full range of symptoms associated with narcolepsy type 1 and is the first approved…
AI Summary: The FDA has approved a medication that treats the full range of narcolepsy symptoms, including excessive daytime sleepiness and cataplexy, marking the first such comprehensive option for patients with narcolepsy type 1. Clinicians now have a single, regulated choice to address multiple debilitating symptoms rather than juggling piecemeal therapies.
NCCS Develops AI Tool to Predict Liver Cancer Recurrence After Surgery
oncodaily - National Cancer Centre Singapore (NCCS) shared on LinkedIn: “Can we now predict who’s at greatest risk for liver cancer recurrence? Congratulations to NCCS’ Professor Pierce Chow, Associate Professor Wai Leong Tam, Mr. Karthik Sekar, […]
AI Summary: A newly developed AI model predicts risk of liver cancer recurrence following surgical resection, integrating imaging and clinical variables to stratify patients more accurately. Early validation suggests the tool could personalize surveillance intensity and adjuvant therapy decisions, reducing unnecessary exams for low‑risk patients while focusing resources where recurrence risk is highest.
Some COVID-19 Patients Suffered Heart Damage, an Overlooked Coronavirus Protein May Explain Why
discovermagazine - Discover how the inconspicuous nucleocapsid protein from coronaviruses can trigger hyperinflammation, an effect not typically seen in other viruses.
AI Summary: Scientists identified a previously underappreciated SARS‑CoV‑2 protein that appears to damage heart tissue and may help explain persistent post‑COVID symptoms. The study ties the viral molecule to mechanisms of cardiac injury, opening diagnostic and therapeutic research paths for long COVID cardiac effects — proof that sometimes the troublemaker was hiding in plain sight.
Tufts Medicine CEO, CFO step down amid financial struggles
Jill Hughes / healthcaredive - Chief Executive Mike Dandorph will remain in the position through the end of September, after which he will be replaced by COO Phil Okala. Tufts is also swapping out its chief financial officer.
AI Summary: Tufts Medicine announced the departure of its CEO and CFO amid ongoing financial struggles, prompting a leadership shake‑up as the health system pursues fiscal stabilization. Trustees and executives are now tasked with steadying operations and advancing a turnaround plan while maintaining patient services — the corporate surgery no one asked for.
New bipartisan 340B reform bill curbs HHS' rebate pilot
fiercehealthcare - The SUSTAIN 340B Act introduced Wednesday would bring hospital-backed changes, like a clearinghouse to handle improper discounts, and codifies longstanding grey areas in the contentious subsidy program.
AI Summary: Bipartisan lawmakers introduced legislation to rein in HHS’s controversial 340B rebate pilot, pushing back on administrative changes that providers say threaten safety‑net funding. The bill aims to pause or limit the pilot while stakeholders debate drug‑pricing impacts, reimbursements and patient access — the predictable Washington policy scrum.